Colony-stimulating factors for chemotherapy-induced febrile neutropenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Mhaskar, Rahul ^a   Clark, Otavio Augusto Camara ^b   Lyman, Gary ^c   Engel Ayer Botrel, Tobias ^d   Morganti Paladini, Luciano ^e   Djulbegovic, Benjamin ^f  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b KANTAR HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Evidence Based Medicine Consultancy   (Brazil)

^e HTA   (Brazil)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTHRALGIA; BONE PAIN; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; LEUKOCYTE; MALIGNANT NEOPLASM; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ADULT; CHEMICALLY INDUCED; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CHILD; DRUG COMBINATION; META ANALYSIS; NEOPLASMS;

ADULT; ANTI-BACTERIAL AGENTS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CHILD; COLONY-STIMULATING FACTORS; DRUG THERAPY, COMBINATION; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84965184341     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003039.pub2     Document Type: Review

References (81)

1. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarjian H, Abi-Said D, et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine 1996;100(1):17-23.
2. Arnberg H, Letocha H, Nou F, Westlin JF, Nilsson S. GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research 1998;18(2B):1255-60.
3. Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-Maqueo JC. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 1996;7(4):392-7.
4. Biesma B, de Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC, et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer 1990;26(9):932-6.
5. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute 2001;93(1):31-8.
6. Lopez-Hernandez MA, Jimenez-Alvarado R, Borbolla-Escoboza R, de Diego Flores-Chapa J, Alvarado-Ibarra M, Gonzalez-Avante M, et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México 2000;136(2):99-105.
7. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1994;121(7):492-501.
8. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute 1995;87(11):803-8.
9. Mitchell PL, Morland B, Stevens MC, Dick G, Easlea D, Meyer LC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology 1997;15(3):1163-70.
10. Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roche H, et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology 1998;16(9):2930-6.
11. Riikonen P, Saarinen UM, Makipernaa A, Hovi L, Komulainen A, Pihkala J, Jalanko H. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal 1994;13(3):197-202.
12. Rodriguez ZN, Tordecilla CJ, Campbell BM, Joannon SP, Rizzardini LC, Soto AV, et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia 2005;22(3):223-7. [PUBMED: 16077888]
13. Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Lowenberg B, ten Haaft MA, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology 1996;14(2):619-27.
14. Yoshida M, Karasawa M, Naruse T, Fukuda M, Hirashima K, Oh H, et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology 1999;69(2):81-8.
15. Balcerska A, Ploszynska A, Polczynska K, Maciejka-Kapuscinska L, Wlazlowski M, Drozynska E, et al. The effect of cytokines G-CSF and GM-CSF in therapy of childhood malignancies [Ocena Skutecznosci Czynnikow Wzrostu G-CSF I GM-CSF W Leczeniu Wspomagajacym Choroby Nowotworowej U Dzieci]. Annales Academiae Medicae Gedanensis 1995;25:117-24.
16. Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Investigation 1998;16(6):366-73.
17. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. European Journal of Clinical Microbiology & Infectious Diseases 1994;13 Suppl 2:S18-22.
18. Feng F, Zhou L. Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 1998;20(6):451-3.
19. Fengyi F, Liqiang Z. Randomized controlled study of leucomax (recombinant human granulocyte- macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 1998;20(6):451-3.
20. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Filgrastim in the treatment of high-risk febrile neutropenia: results of a multicenter randomized phase III trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract #2253.
21. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia. European Journal of Cancer 1999;35(Supplement 4):360.
22. Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N. A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Research 1994;14(2B):731-4.
23. Gunay U, Tanritanir A, Meral A, Sevinir BB, Hacimollaoglu MK. The effects of granulocyte colony-stimulating factor (G-CSF) and intravenous immunoglobulin (IVIG) on the treatment of neutropenic fever in children. Cocuk Sagligi Ve Hastaliklari Dergisi 1998;41(4):433-44.
24. Herrmann F, Schulz G, Wieser M, Kolbe K, Nicolay U, Noack M, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. The American Journal of Medicine 1990;88(6):619-24.
25. Kaku K, Takahashi M, Moriyama Y, Nakahata T, Masaoka T, Yoshida Y, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial. Leukemia and Lymphoma 1993;11(3-4):229-38.
26. Kawa K, Keiko Y, Dong PY, Sako M, Tanaka H, Hara J, et al. A multi-institutional study of optimal use of recombinant granulocyte colony stimulating factor (lenograstim) in pediatric malignancies - III. Biotherapy 1999;13(4):361-7.
27. Kotake T, Usami M, Miki T, Togashi M, Akaza H, Kubota Y, et al. Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer. International Journal of Urology 1999;6(2):61-7.
28. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes MP, Lopez-Brea M, López E. Progress report of a randomized trial on the value of adding G-CSF or GM-CSF to standard antibiotic therapy in the treatment of febrile neutropenia. Annals of Oncology 1992;3(Supplement 5: Growth factors/Oncogenes/Tumour suppressor):2.
29. Mayordomo JI, Rivera F, Diaz Puente MT, Lianes MP, Lopez-Brea M, Lopez E, et al. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1993; Vol. 12:Abstract # 1510.
30. Michon JM, Hartmann O, Bouffet E, Meresse V, Coze C, Rubie H, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. European Journal of Cancer 1998;34(7):1063-9.
31. Montalar J, Santaballa A, Oltra A, Segura A, Aparicio A, Pastor M. Ofloxacin with or without stimulating colony-factors in the treatment of neutropenic fever. Annals of Oncology 1998;9(Supplement 4 palliative and supportive care):151 abstract #724.
32. Moriyama Y, Takahashi M, Kaku K, Yoshida Y, Masaoka T, Nakanishi S, et al. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced granulocytopenia in patients with malignancies. Acta Haematologica 1993;89(2):70-5.
33. Motoyoshi K, Takaku F, Maekawa T, Miura Y, Kimura K, Furusawa S, et al. Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy. Experimental Hematology 1986;14(11):1069-75.
34. Nakajima H, Ikeda Y, Hirashima K, Toyama K, Okuma M, Saito H, et al. A randomized controlled study of rG.CSF in patients with neutropenia after induction therapy for acute myelogenous leukemia. (rG.CSF Clinical Study Group). Rinsho Ketsueki [The Japanese Journal of Clinical Hematology] 1995;36(6):597-605.
35. Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A, et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. Journal of Clinical Oncology 1997;15(8):2954-65.
36. Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer. American Journal of Clinical Oncology 2000;23(3):278-82.
37. Ravaud A, Chevreau C, Bonichon F, Mihura J, Bui BN, Tabah I. A phase III trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) as corrective treatment in patients (pts) with neutropenic fever following antineoplastic chemotherapy (CT): results of an intermediate analysis. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995:Abstract A716.
38. Schroder CP, de Vries EG, Mulder NH, Willemse PH, Sleijfer DT, Hospers GA, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. The Journal of Antimicrobial Chemotherapy 1999;43(5):741-3.
39. Soda H, Oka M, Fukuda M, Kinoshita A, Sakamoto A, Araki J, et al. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 1996;38(1):9-12.
40. Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. Journal of Clinical Oncology 2005;23(31):7974-84. [PUBMED: 16258098]
41. Torrecillas L, Cervantes G, Zamora R, Acosta A, Cepeda F, Cortés P, et al. GM-CSF discontinuation safe level for patients with chemotherapy induced febrile or afebrile neutropenia. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:Abstract #304.
42. Uyl-de Groot CA, Vellenga E, de Vries EG, Lowenberg B, Stoter GJ, Rutten FF. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial. Pharmacoeconomics 1997;12(3):351-60.
43. van Pelt LJ, de Craen AJ, Langeveld NE, Weening RS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors. Pediatric Hematology and Oncology 1997;14(6):539-45.
44. Vellenga E, Uyl-De Groot C, Stoter G, Lowenberg B, De Vries E. Faster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay. Nederlands Tijdschrift voor Geneeskunde 1996;140(32):1650-5.
45. Yalcin S, Guler N, Kansu E, Ertenli I, Gullu I, Barista I, et al. Granulocyte-colony stimulating factor (G-CSF) administration for chemotherapy-induced neutropenia. Hematology 1996;1(2):155-61.
46. Yamazaki K, Kumamoto Y, Tsukamoto T, Hirose T. Prophylaxis of fever during leukocytopenia by anticancer chemotherapy. Chemotherapy 1989;37(6):838-47.
47. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer 2002;10(3):181-8. [MEDLINE: 11904782]
48. Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Medical Journal 1999;117(3):138-9.
49. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology 2010;21 Suppl 5:v252-v6.
50. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91.
51. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
52. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. 2nd Edition. London: BMJ Books, 2001.
53. Freyer G, Ligneau B, Trillet-Lenoir V. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia. International Journal of Antimicrobial Agents 1998;10(1):3-9.
54. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infectious Disease Clinics of North America 2001;15(2):457-82.
55. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
56. Griffin JD. Hematopoietic growth factors. In: DeVitaJr VT, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
57. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
58. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
59. Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
60. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
61. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - risk of bias. Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
62. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
64. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
65. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
66. Higgins JPT, Altman DG, Sterne JAC. Chapter 16.5.4: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
67. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5:13. [PUBMED: 15840177]
68. Hozo I, Djulbegovic B, Clark O, Lyman GH. Use of re-randomized data in meta-analysis. BMC Medical Research Methodology 2005;10(5):17.
69. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. The Journal of Infectious Diseases 1990;161(3):397-401.
70. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine 2002;112(5):406-11.
71. Mhaskar Rahul, Djulbegovic Benjamin, Magazin Anja, Soares Heloisa P, Kumar Ambuj. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology 2012;65(6):602-9.
72. Moher D, Liberati A, TetzlaffJ, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
73. Paesmans M. Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia. Supportive Care in Cancer 1998;6(5):438-43.
74. Petros WP. Colony-stimulating factors. In: Chabner BA, Longo DL editor(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. 5th Edition. Lippincott Williams & Wilkins, 2001.
75. Pizzo PA. Fever in immunocompromised patients. The New England Journal of Medicine 1999;341(12):893-900.
76. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
77. Rubenstein EB. Colony stimulating factors in patients with fever and neutropenia. International Journal of Antimicrobial Agents 2000;16(2):117-21.
78. Segal BH, Walsh TJ, Holland SM. Infections in the cancer patient. In: DeVitaJr VT, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
79. Smeenk FW, van Haastregt JC, de Witte LP, Crebolder HF. Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review. BMJ 1998;316(7149):1939-44.
80. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
81. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database of Systematic Reviews 2000, issue 3. [DOI: 10.1002/14651858.CD003039;: CD003039]